Literature DB >> 19659896

Experimental mouse models for hepatocellular carcinoma research.

Femke Heindryckx1, Isabelle Colle, Hans Van Vlierberghe.   

Abstract

Every year almost 500,000 new patients are diagnosed with hepatocellular carcinoma (HCC), a primary malignancy of the liver that is associated with a poor prognosis. Numerous experimental models have been developed to define the pathogenesis of HCC and to test novel drug candidates. This review analyses several mouse models useful for HCC research and points out their advantages and weaknesses. Chemically induced HCC mice models mimic the injury-fibrosis-malignancy cycle by administration of a genotoxic compound alone or, if necessary, followed by a promoting agent. Xenograft models develop HCC by implanting hepatoma cell lines in mice, either ectopically or orthotopically; these models are suitable for drug screening, although extrapolation should be considered with caution as multiple cell lines must always be used. The hollow fibre assay offers a solution for limiting the number of test animals in xenograft research because of the ability for implanting multiple cell lines in one mouse. There is also a broad range of genetically modified mice engineered to investigate the pathophysiology of HCC. Transgenic mice expressing viral genes, oncogenes and/or growth factors allow the identification of pathways involved in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659896      PMCID: PMC2741148          DOI: 10.1111/j.1365-2613.2009.00656.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  172 in total

1.  HCV-associated hepatocellular carcinoma without cirrhosis.

Authors:  A el-Refaie; K Savage; S Bhattacharya; S Khakoo; T J Harrison; M el-Batanony; S Nasr; N Mokhtar; K Amer; P J Scheuer; A P Dhillon
Journal:  J Hepatol       Date:  1996-03       Impact factor: 25.083

2.  Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.

Authors:  T L Mao; J S Chu; Y M Jeng; P L Lai; H C Hsu
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

3.  Age- and sex-associated diethylnitrosamine dealkylation activity of the mouse liver and hepatocarcinogenesis.

Authors:  K V Rao; S D Vesselinovitch
Journal:  Cancer Res       Date:  1973-07       Impact factor: 12.701

4.  Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours.

Authors:  Jürgen Borlak; Tatiana Meier; Roman Halter; Reinhard Spanel; Katharina Spanel-Borowski
Journal:  Oncogene       Date:  2005-03-10       Impact factor: 9.867

5.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors:  Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

6.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

7.  Role of phenobarbital-inducible cytochrome P450s as a source of active oxygen species in DNA-oxidation.

Authors:  Susumu Imaoka; Mayuko Osada; Yukiko Minamiyama; Tokihito Yukimura; Shinya Toyokuni; Shigekazu Takemura; Toyoko Hiroi; Yoshihiko Funae
Journal:  Cancer Lett       Date:  2004-01-20       Impact factor: 8.679

Review 8.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

9.  Hepatotoxicity due to clofibrate is oxygen-dependent in the perfused rat liver.

Authors:  B J Keller; H Yamanaka; D C Liang; R G Thurman
Journal:  Toxicol Appl Pharmacol       Date:  1990-06-15       Impact factor: 4.219

10.  TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop.

Authors:  Tae Jun Park; Ji Yeon Kim; S Paul Oh; So Young Kang; Bong Wan Kim; Hee Jung Wang; Kye Yong Song; Hyoung Chin Kim; In Kyoung Lim
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

View more
  141 in total

Review 1.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

Review 2.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

3.  Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells.

Authors:  Su Mi Choi; Yonghak Kim; Hua Liu; Pooja Chaudhari; Zhaohui Ye; Yoon-Young Jang
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 4.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

5.  Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model.

Authors:  Xing Wang; Juan Zhang; Liang Zhou; Peng Lu; Zhi-Gang Zheng; Wei Sun; Jian-Lin Wang; Xi-Sheng Yang; Xiao-Lei Li; Ning Xia; Ning Zhang; Ke-Feng Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

6.  Effects of Wnt-1 blockade in DEN-induced hepatocellular adenomas of mice.

Authors:  Argyrios Sklavos; Theofilos Poutahidis; Alexander Giakoustidis; Kali Makedou; Katerina Angelopoulou; Alexander Hardas; Paola Andreani; Argyro Zacharioudaki; George Saridis; Thomas Goulopoulos; Kalliopi Tsarea; Maria Karamperi; Vassilios Papadopoulos; Vassilios Papanikolaou; Apostolos Papalois; Stavros Iliadis; Satvinder Mudan; Daniel Azoulay; Dimitrios Giakoustidis
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

7.  Dissecting the pleiotropic actions of HBx mutants against hypoxia in hepatocellular carcinoma.

Authors:  Ying-Ying Lee; Myth T S Mok; Alfred Sze-Lok Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

8.  Integrative genomic analysis of mouse and human hepatocellular carcinoma.

Authors:  Michelle Dow; Rachel M Pyke; Brian Y Tsui; Ludmil B Alexandrov; Hayato Nakagawa; Koji Taniguchi; Ekihiro Seki; Olivier Harismendy; Shabnam Shalapour; Michael Karin; Hannah Carter; Joan Font-Burgada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-04       Impact factor: 11.205

9.  Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma.

Authors:  Julia Freimuth; Nikolaus Gassler; Nives Moro; Rolf W Günther; Christian Trautwein; Christian Liedtke; Gabriele A Krombach
Journal:  Mol Cancer       Date:  2010-04-29       Impact factor: 27.401

Review 10.  Alpha-fetoprotein-targeted reporter gene expression imaging in hepatocellular carcinoma.

Authors:  Kwang Il Kim; Hye Kyung Chung; Ju Hui Park; Yong Jin Lee; Joo Hyun Kang
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.